Pattern of drug use in patients with psoriatic arthritis in Italy: study in a real-world setting

References

• Marchesoni A, Lubrano E, Manara M, et al. Current approach to the management of psoriatic arthritis according to a sample of Italian rheumatologists. Clin Exp Rheumatol. 2016;34(6):1051–1058.
   PubMed Web of Science ®Google Scholar
• Felquer MLA, FitzGerald O. Peripheral joint involvement in psoriatic arthritis patients. Clin Exp Rheumatol. 2015;33:S26–S30.
   Web of Science ®Google Scholar
• Singh JA, Guyatt G, Ogdie A, et al. American college of rheumatology/national psoriasis foundation guideline for the treatment of psoriatic Arthritis. Arthritis Care Res. 2018;2019(71):2–29.
   Google Scholar
• Belasco J, Wei N. Psoriatic arthritis: what is happening at the joint? Rheumatol Ther. 2019;6(3):305–315.
   PubMed Web of Science ®Google Scholar
• Scotti L, Franchi M, Marchesoni A, et al. Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2018;48(1):28–34.
   PubMed Web of Science ®Google Scholar
• Prignano F, Rogai V, Cavallucci E, et al. Epidemiology of psoriasis and psoriatic arthritis in Italy-a systematic review. Curr Rheumatol Rep.. 2018;20(7):43.
   PubMed Web of Science ®Google Scholar
• Sarzi-Puttini P, Ceribelli A, Marotto D, et al. Systemic rheumatic diseases: from biological agents to small molecules. Autoimmun Rev. 2019;18(6):583–592.
   PubMed Web of Science ®Google Scholar
• Gossec L, Baraliakos X, Kerschbaumer A, et al., EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 79(6): 700–712. 2020.
   PubMed Web of Science ®Google Scholar
• Gazzetta Ufficiale. https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2017-02-10&atto.codiceRedazionale=17A00544&elenco30giorni=false (accessed 2019 Jul 13).
   Google Scholar
• Marchesoni A, Olivieri I, Salvarani C, et al. Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian society of rheumatology. Clin Exp Rheumatol. 2017;35(6):991–1010.
   PubMed Web of Science ®Google Scholar
• Chatzidionysiou K, Hetland ML, Frisell T, et al. Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the nordic example. RMD Open. 2018;4:e000655.
   PubMed Web of Science ®Google Scholar
• Ogdie A, Coates L. The changing face of clinical trials in psoriatic arthritis. Curr Rheumatol Rep.. 2017;19(4):21.
   PubMed Web of Science ®Google Scholar
• Murage MJ, Tongbram V, Feldman SR, et al. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adherence. 2018;12:1483–1503.
   PubMed Web of Science ®Google Scholar
• D’Angelo S, Tramontano G, Gilio M, et al. Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatol.. 2017;9:21–2817.
   PubMed Web of Science ®Google Scholar
• Costa L, Perricone C, Chimenti MS, et al. Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs R D.. 2017;17(4):509–522.
   PubMed Web of Science ®Google Scholar
• Agenzia Italiana del Farmaco (AIFA). Guideline for the classification and conduction of the observational studies on medicines, http://www.agenziafarmaco.gov.it/allegati/det_20marzo2008.pdf [accessed 2019 Oct 14].
   Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• FitzGerald O, Ritchlin C. Opportunities and challenges in the treatment of psoriatic arthritis. Best Pract Res Clin Rheumatol.. 2018;32(3):440–452.
   PubMed Web of Science ®Google Scholar
• Degli Esposti L, Perrone V, Sangiorgi D, et al. Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies. Biologics. 2018;12:151–158.
   PubMedGoogle Scholar
• Esposti LD, Perrone V, Sangiorgi D, et al. Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting. Patient Pref Adherence.. 2019;13:187–194.
   PubMed Web of Science ®Google Scholar
• Zhang HF, Gauthier G, Hiscock R, et al. Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs. Arthritis Res Ther. 2014;16(4):420.
   PubMed Web of Science ®Google Scholar
• Zhu B, Edson-Heredia E, Gatz JL, et al. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study. Clin Ther. 2013;35(9):1376–1385.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Zhao Y, Shi L, et al. Economic and comorbidity burden among patients with moderate-to-severe psoriasis. J Manag Care Spec Pharm.. 2015;21(10):874–888.
   PubMed Web of Science ®Google Scholar
• Lyu R, Govoni M, Ding Q, et al. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany. Rheumatol Int.. 2016;36(1):143–153.
   PubMed Web of Science ®Google Scholar
• Merola JF, Lockshin B, Mody EA. Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum. 2017;47(1):29–37.
   PubMed Web of Science ®Google Scholar
• Bonafede M, Fox KM, Watson C, et al. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther. 2012;29(8):664–674.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Karki C, Liu M, et al. Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based corrona registry. RMD Open. 2019;5(1):e000880.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Ostergaard M, Krogh NS, et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the danish nationwide DANBIO registry. Arthritis Rheum. 2013;65(5):1213–1223.
   PubMed Web of Science ®Google Scholar
• Saad AA, Ashcroft DM, Watson KD, et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British society of rheumatology biologics register. Arthritis Res Ther. 2009;11(2):R52.
   PubMed Web of Science ®Google Scholar
• Walsh JA, Cai Q, Lin I, et al. Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies. Curr Med Res Opin. 2020;0(0):1–8.
   Google Scholar
• Oelke KR, Chambenoit O, Majjhoo AQ, et al. Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database. J Comp Eff Res. 2019;8(8):607–621.
   PubMed Web of Science ®Google Scholar